Posted by Michael Wonder on 10 Oct 2020
Health Canada approves Inqovi (decitabine and cedazuridine) oral therapy for two types of blood cancers, MDS and CMML
8 October 2020 - Oral drug can be taken at home, which may enable some patients to avoid some hospital visits.
Taiho Pharma Canada today announces that Health Canada approved Inqovi as the first and only orally administered hypomethylating agent for the treatment of adults with intermediate-1, intermediate-2 and high-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia, two blood malignancies.
Inqovi was developed by Astex Pharmaceuticals, a sister company of Taiho and will be available in Canada.
